News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novum Pharmaceutical Research Services Opens New Clinical Research Facility In Las Vegas, Nevada



10/19/2005 5:10:29 PM

PITTSBURGH, March 17 /PRNewswire/ -- Novum Pharmaceutical Research Services, a company specializing in the conduct of clinical research for the generic, pharmaceutical and biotechnology industries, announces the opening of a new Phase I facility in Las Vegas, Nevada.

"Following a survey of our clients last year, it was clear that the ability to offer quicker start up times and a more diverse population of study participants were high on our clients' lists of priorities. The opening of our third facility will enable Novum to significantly improve our ability to meet our clients' requests," said Chris Hendy, Ph.D., President and CEO of Novum. "Las Vegas is the fastest growing city in the United States with a population well in excess of 1 million people. With its unique employment patterns and its diverse demographic profile we believe this is an excellent city in which to develop a research unit. We have been delighted by the support shown to us by the Nevada Development Agency and the State of Nevada. In addition, we are already developing excellent relationships with the local medical community, which we believe will allow us to offer some specialized research capabilities at this new facility."

The 21,000 square foot facility, which will consist of 3 clinics with a total of 120 beds, is situated just three miles from McCarren International Airport and less than five miles from the world famous Las Vegas Strip. The addition of the new Las Vegas facility to its already established research clinics in Pittsburgh, Pennsylvania and Houston, Texas will result in Novum having access to approximately 500 Phase I research beds.

Novum Pharmaceutical Research Services has been a leading provider of clinical research services to the pharmaceutical industry for over 25 years. In 2003, the FDA issued twenty-four marketing approvals from studies conducted at Novum.

For more information on Novum's Phase I and clinical trials capabilities, contact Jenny Lytle, Associate Director, Client Services, Novum Pharmaceutical Research Services, 5900 Penn Avenue, Pittsburgh, PA 15206. Tel: (412) 363-3300 ext. 605, Fax: (412) 362-5783, E-mail: jrlytle@novumprs.com.

Novum Pharmaceutical Research Services

CONTACT: Jenny Lytle, Associate Director, Client Services of NovumPharmaceutical Research Services, +1-412-363-3300 ext. 605, or fax,+1-412-362-5783, or e-mail, jrlytle@novumprs.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES